BDBM100852 US8507533, 170::US8507533, 419

SMILES Cc1cc(cc(C)c1-n1cc(cn1)C(F)(F)F)C(Nc1ccc(cn1)C(=O)NCCC(O)=O)C1CCCC1

InChI Key InChIKey=CCMSZNRJWBLATB-UHFFFAOYSA-N

Data  2 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 100852   

TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100852(US8507533, 170 | US8507533, 419)
Affinity DataKi:  28nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100852(US8507533, 170 | US8507533, 419)
Affinity DataKi:  224nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent